

Shicheng Guo <shg047@eng.ucsd.edu>

Thank you for submitting your review of Manuscript ID LCNV-2015-0175 for Cancer Investigation

1 message

GLyman@fhcrc.org <GLyman@fhcrc.org>

Tue, Jun 23, 2015 at 4:04 PM

To: scguo@ucsd.edu

23-Jun-2015

Dear Dr Shicheng Guo:

Thank you for reviewing the above manuscript, entitled "A multi-center phase II study of nintedanib as second-line therapy for patients with advanced non-small-cell lung cancer in China" for Cancer Investigation.

We greatly appreciate the voluntary contribution that each reviewer gives to the Journal. We hope that we may continue to seek your assistance with the refereeing process for Cancer Investigation, and hope also to receive your own research papers that are appropriate to our aims and scope.

Sincerely, Professor Gary Lyman Cancer Investigation GLyman@FHCRC.ORG